PUBLISHER: Fortune Business Insights Pvt. Ltd. | PRODUCT CODE: 1933381
PUBLISHER: Fortune Business Insights Pvt. Ltd. | PRODUCT CODE: 1933381
Gastrointestinal Therapeutics Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2026-2034
Growth Factors of gastrointestinal (GI) therapeutics Market
The global gastrointestinal (GI) therapeutics market is witnessing consistent growth, driven by the rising prevalence of digestive disorders, increasing awareness, and continuous innovation in drug development. Gastrointestinal therapeutics include medications for conditions such as gastroesophageal reflux disease (GERD), inflammatory bowel disease (IBD), irritable bowel syndrome (IBS), GI cancers, and other functional GI disorders. According to Fortune Business Insights, the global gastrointestinal therapeutics market was valued at USD 80.60 billion in 2025, highlighting the significant demand for effective digestive health treatments worldwide.
Market Size and Forecast
In 2026, the global market is projected to grow to USD 89.11 billion, supported by increasing diagnosis rates, strong demand for acid suppression therapies, and expanding use of biologics for chronic GI conditions. Over the long term, the market is expected to reach USD 140.98 billion by 2034, registering a CAGR of 5.09% during the forecast period.
North America dominated the global gastrointestinal therapeutics market in 2025, accounting for a 42.32% market share, owing to high disease prevalence, strong healthcare infrastructure, and early adoption of advanced therapies.
Market Drivers
One of the key drivers fueling market growth is the increasing prevalence of gastrointestinal diseases globally. Lifestyle changes such as unhealthy diets, sedentary behavior, rising alcohol consumption, and stress have significantly contributed to the growing burden of GI disorders. This expanding patient population has increased demand for effective therapeutic solutions and advanced diagnostic procedures.
According to the Crohn's & Colitis Foundation, between 1.6 and 3.1 million people in the U.S. were living with inflammatory bowel disease as of June 2023, underscoring the need for long-term disease management and driving pharmaceutical innovation.
Market Restraints
Despite steady growth, the market faces restraints due to the high cost of advanced therapies, particularly biologics and targeted treatments. These therapies require extensive R&D investment, making them expensive and less accessible, especially in low- and middle-income countries. Limited insurance coverage further increases the financial burden on patients.
For example, the bundled cost of a 5 mg/kg dose of infliximab was reported at approximately USD 2,634 in the U.S., limiting affordability and slowing adoption of advanced therapies.
Market Opportunities
The rising focus on biologics and targeted therapies presents significant growth opportunities. Unlike conventional drugs that offer symptomatic relief, biologics target specific inflammatory pathways, providing improved efficacy and long-term remission, particularly in IBD patients. Additionally, the development of biosimilars and next-generation oral therapies is expected to improve affordability and market penetration.
In June 2024, the U.S. FDA approved SKYRIZI (risankizumab-rzaa) for moderately to severely active ulcerative colitis, reflecting the growing momentum in biologic drug adoption.
Market Trends
A prominent trend shaping the market is the increased emphasis on early screening and preventive diagnostics. Healthcare systems are focusing on early detection of GI cancers and chronic conditions through molecular diagnostics, biomarker testing, and AI-enabled endoscopic imaging. These advancements improve patient outcomes while supporting demand for integrated therapeutic and diagnostic solutions.
Market Challenges
A major challenge limiting market expansion is the risk of adverse drug reactions and long-term safety concerns associated with commonly used GI medications. For instance, prolonged use of proton pump inhibitors (PPIs) has been linked to kidney disease, nutrient deficiencies, bone fractures, and infections. Regulatory warnings and cautious prescribing practices have moderated growth in certain traditional drug segments.
Segmentation Analysis
By product type, small molecules and conventional drugs dominated the market, holding a 71.36% share in 2026, driven by affordability and widespread availability.
By therapy type, acid suppression therapies led the market with a 23.84% share in 2026, supported by high GERD prevalence and strong OTC demand.
By route of administration, the oral segment dominated with a 70.41% share in 2026, due to convenience and high patient adherence.
By application, inflammatory bowel disease (IBD) accounted for the largest share, driven by high treatment costs and rising patient awareness.
By distribution channel, retail pharmacies and drug stores led the market, holding 50.9% share in 2025.
Regional Outlook
North America led the market with USD 35.80 billion in 2025 and USD 37.69 billion in 2026, driven by strong R&D activity and high disease burden.
Europe reached USD 21.81 billion in 2025, while Asia Pacific recorded USD 20.95 billion in 2025, supported by improving healthcare infrastructure in China and India.
Latin America and Middle East & Africa showed moderate growth, with valuations of USD 3.44 billion and USD 1.26 billion respectively in 2025.
Competitive Landscape
The global market is semi-consolidated, with key players such as AbbVie Inc., Johnson & Johnson, Takeda Pharmaceutical Company Limited, Pfizer Inc., and Bristol Myers Squibb leading due to diversified portfolios, strong pipelines, and global distribution networks. Continuous product approvals and biologic innovation support their dominance.
Conclusion
The global gastrointestinal therapeutics market is set to grow steadily from USD 80.60 billion in 2025 to USD 140.98 billion by 2034, driven by rising prevalence of GI disorders, expanding use of biologics, and growing focus on early diagnosis and preventive care. Although high treatment costs and safety concerns pose challenges, continuous R&D investments, targeted therapies, and biosimilar development are expected to enhance treatment accessibility and long-term disease management. Overall, the market will continue to evolve as a critical component of global healthcare, addressing the increasing burden of digestive diseases worldwide.
Segmentation By Product Type
- Small Molecules/Conventional Drugs
- Biologics & Biosimilars
By Therapy Type
Acid Suppression Therapies
- Proton Pump Inhibitor (PPI)
- Others
- Targeted Therapies
- Antibodies
- JAK Inhibitors
- Others
- Anti-Inflammatory & Immunomodulators
- Antibiotics
- Antiemetics
- Motility Agents & Secretagogues
- Others
By Route of Administration
- Oral
- Parenteral
- Others
By Age Group
- Pediatrics
- Adults
By Application
- Gastroesophageal Reflux Disease (GERD)
- Functional Gastrointestinal Disorders (FGIDs)
- Inflammatory Bowel Disease (IBD)
- Irritable Bowel Syndrome (IBS)
- GI Cancers
- Others
By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies & Drug Stores
- Online Pharmacies
By Region
North America (By Product Type, Therapy Type, Route of Administration, Age Group, Application, Distribution Channel, and Country)
- U.S.
- Canada
Europe (By Product Type, Therapy Type, Route of Administration, Age Group, Application, Distribution Channel, and Country/Sub-region)
- Germany
- U.K.
- France
- Spain
- Italy
- Scandinavia
- Rest of Europe
Asia Pacific (By Product Type, Therapy Type, Route of Administration, Age Group, Application, Distribution Channel, and Country/Sub-region)
- China
- Japan
- India
- Australia
- Southeast Asia
- Rest of Asia Pacific
Latin America (By Product Type, Therapy Type, Route of Administration, Age Group, Application, Distribution Channel, and Country/Sub-region)
- Brazil
- Mexico
- Rest of Latin America
Middle East & Africa (By Product Type, Therapy Type, Route of Administration, Age Group, Application, Distribution Channel, and Country/Sub-region)
- GCC
- South Africa
- Rest of the Middle East & Africa
Table of Content
1. Introduction
- 1.1. Research Scope
- 1.2. Market Segmentation
- 1.3. Research Methodology
- 1.4. Definitions and Assumptions
2. Executive Summary
3. Market Dynamics
- 3.1. Market Drivers
- 3.2. Market Restraints
- 3.3. Market Opportunities
- 3.4. Market Trends
4. Key Insights
- 4.1. Overview: Technological Advancements in Gastrointestinal Therapeutics
- 4.2. Regulatory Scenario, By Key Countries/Regions
- 4.3. Key Industry Developments (Mergers, Acquisitions, and Collaborations etc.)
- 4.4. New Product Launches, By Key Players
5. Global Gastrointestinal Therapeutics Market Analysis, Insights and Forecast, 2021-2034
- 5.1. Market Analysis, Insights and Forecast - By Product Type Type
- 5.1.1. Small Molecules/Conventional Drugs
- 5.1.2. Biologics & Biosimilars
- 5.2. Market Analysis, Insights and Forecast - By Therapy Type
- 5.2.1. Acid Suppression Therapies
- 5.2.1.1. Proton Pump Inhibitor (PPI)
- 5.2.1.2. Others
- 5.2.2. Targeted Therapies
- 5.2.2.1. Antibodies
- 5.2.2.2. JAK Inhibitors
- 5.2.2.3. Others
- 5.2.3. Anti-Inflammatory & Immunomodulators
- 5.2.4. Antibiotics
- 5.2.5. Antiemetics
- 5.2.6. Motility Agents & Secretagogues
- 5.2.7. Others
- 5.2.1. Acid Suppression Therapies
- 5.3. Market Analysis, Insights and Forecast - By Route of Administration
- 5.3.1. Oral
- 5.3.2. Parenteral
- 5.3.3. Others
- 5.4. Market Analysis, Insights and Forecast - By Age Group
- 5.4.1. Pediatrics
- 5.4.2. Adults
- 5.5. Market Analysis, Insights and Forecast - By Application
- 5.5.1. Gastroesophageal Reflux Disease (GERD)
- 5.5.2. Functional Gastrointestinal Disorders (FGIDs)
- 5.5.3. Irritable Bowel Syndrome (IBS)
- 5.5.4. Inflammatory Bowel Disease (IBD)
- 5.5.5. GI Cancers
- 5.5.6. Others
- 5.6. Market Analysis, Insights and Forecast - By Distribution Channel
- 5.6.1. Hospital Pharmacies
- 5.6.2. Retail Pharmacies & Drug Stores
- 5.6.3. Online Pharmacies
- 5.7. Market Analysis, Insights and Forecast - By Region
- 5.7.1. North America
- 5.7.2. Europe
- 5.7.3. Asia Pacific
- 5.7.4. Latin America
- 5.7.5. Middle East & Africa
6. North America Gastrointestinal Therapeutics Market Analysis, Insights and Forecast, 2021-2034
- 6.1. Market Analysis, Insights and Forecast - By Product Type Type
- 6.1.1. Small Molecules/Conventional Drugs
- 6.1.2. Biologics & Biosimilars
- 6.2. Market Analysis, Insights and Forecast - By Therapy Type
- 6.2.1. Acid Suppression Therapies
- 6.2.1.1. Proton Pump Inhibitor (PPI)
- 6.2.1.2. Others
- 6.2.2. Targeted Therapies
- 6.2.2.1. Antibodies
- 6.2.2.2. JAK Inhibitors
- 6.2.2.3. Others
- 6.2.3. Anti-Inflammatory & Immunomodulators
- 6.2.4. Antibiotics
- 6.2.5. Antiemetics
- 6.2.6. Motility Agents & Secretagogues
- 6.2.7. Others
- 6.2.1. Acid Suppression Therapies
- 6.3. Market Analysis, Insights and Forecast - By Route of Administration
- 6.3.1. Oral
- 6.3.2. Parenteral
- 6.3.3. Others
- 6.4. Market Analysis, Insights and Forecast - By Age Group
- 6.4.1. Pediatrics
- 6.4.2. Adults
- 6.5. Market Analysis, Insights and Forecast - By Application
- 6.5.1. Gastroesophageal Reflux Disease (GERD)
- 6.5.2. Functional Gastrointestinal Disorders (FGIDs)
- 6.5.3. Irritable Bowel Syndrome (IBS)
- 6.5.4. Inflammatory Bowel Disease (IBD)
- 6.5.5. GI Cancers
- 6.5.6. Others
- 6.6. Market Analysis, Insights and Forecast - By Distribution Channel
- 6.6.1. Hospital Pharmacies
- 6.6.2. Retail Pharmacies & Drug Stores
- 6.6.3. Online Pharmacies
- 6.7. Market Analysis, Insights and Forecast - By Country
- 6.7.1. U.S.
- 6.7.2. Canada
7. Europe Gastrointestinal Therapeutics Market Analysis, Insights and Forecast, 2021-2034
- 7.1. Market Analysis, Insights and Forecast - By Product Type Type
- 7.1.1. Small Molecules/Conventional Drugs
- 7.1.2. Biologics & Biosimilars
- 7.2. Market Analysis, Insights and Forecast - By Therapy Type
- 7.2.1. Acid Suppression Therapies
- 7.2.1.1. Proton Pump Inhibitor (PPI)
- 7.2.1.2. Others
- 7.2.2. Targeted Therapies
- 7.2.2.1. Antibodies
- 7.2.2.2. JAK Inhibitors
- 7.2.2.3. Others
- 7.2.3. Anti-Inflammatory & Immunomodulators
- 7.2.4. Antibiotics
- 7.2.5. Antiemetics
- 7.2.6. Motility Agents & Secretagogues
- 7.2.7. Others
- 7.2.1. Acid Suppression Therapies
- 7.3. Market Analysis, Insights and Forecast - By Route of Administration
- 7.3.1. Oral
- 7.3.2. Parenteral
- 7.3.3. Others
- 7.4. Market Analysis, Insights and Forecast - By Age Group
- 7.4.1. Pediatrics
- 7.4.2. Adults
- 7.5. Market Analysis, Insights and Forecast - By Application
- 7.5.1. Gastroesophageal Reflux Disease (GERD)
- 7.5.2. Functional Gastrointestinal Disorders (FGIDs)
- 7.5.3. Irritable Bowel Syndrome (IBS)
- 7.5.4. Inflammatory Bowel Disease (IBD)
- 7.5.5. GI Cancers
- 7.5.6. Others
- 7.6. Market Analysis, Insights and Forecast - By Distribution Channel
- 7.6.1. Hospital Pharmacies
- 7.6.2. Retail Pharmacies & Drug Stores
- 7.6.3. Online Pharmacies
- 7.7. Market Analysis, Insights and Forecast - By Country/Sub-region
- 7.7.1. U.K.
- 7.7.2. Germany
- 7.7.3. France
- 7.7.4. Spain
- 7.7.5. Italy
- 7.7.6. Scandinavia
- 7.7.7. Rest of Europe
8. Asia Pacific Gastrointestinal Therapeutics Market Analysis, Insights and Forecast, 2021-2034
- 8.1. Market Analysis, Insights and Forecast - By Product Type Type
- 8.1.1. Small Molecules/Conventional Drugs
- 8.1.2. Biologics & Biosimilars
- 8.2. Market Analysis, Insights and Forecast - By Therapy Type
- 8.2.1. Acid Suppression Therapies
- 8.2.1.1. Proton Pump Inhibitor (PPI)
- 8.2.1.2. Others
- 8.2.2. Targeted Therapies
- 8.2.2.1. Antibodies
- 8.2.2.2. JAK Inhibitors
- 8.2.2.3. Others
- 8.2.3. Anti-Inflammatory & Immunomodulators
- 8.2.4. Antibiotics
- 8.2.5. Antiemetics
- 8.2.6. Motility Agents & Secretagogues
- 8.2.7. Others
- 8.2.1. Acid Suppression Therapies
- 8.3. Market Analysis, Insights and Forecast - By Route of Administration
- 8.3.1. Oral
- 8.3.2. Parenteral
- 8.3.3. Others
- 8.4. Market Analysis, Insights and Forecast - By Age Group
- 8.4.1. Pediatrics
- 8.4.2. Adults
- 8.5. Market Analysis, Insights and Forecast - By Application
- 8.5.1. Gastroesophageal Reflux Disease (GERD)
- 8.5.2. Functional Gastrointestinal Disorders (FGIDs)
- 8.5.3. Irritable Bowel Syndrome (IBS)
- 8.5.4. Inflammatory Bowel Disease (IBD)
- 8.5.5. GI Cancers
- 8.5.6. Others
- 8.6. Market Analysis, Insights and Forecast - By Distribution Channel
- 8.6.1. Hospital Pharmacies
- 8.6.2. Retail Pharmacies & Drug Stores
- 8.6.3. Online Pharmacies
- 8.7. Market Analysis, Insights and Forecast - By Country/Sub-region
- 8.7.1. Japan
- 8.7.2. China
- 8.7.3. India
- 8.7.4. Australia
- 8.7.5. Southeast Asia
- 8.7.6. Rest of Asia Pacific
9. Latin America Gastrointestinal Therapeutics Market Analysis, Insights and Forecast, 2021-2034
- 9.1. Market Analysis, Insights and Forecast - By Product Type Type
- 9.1.1. Small Molecules/Conventional Drugs
- 9.1.2. Biologics & Biosimilars
- 9.2. Market Analysis, Insights and Forecast - By Therapy Type
- 9.2.1. Acid Suppression Therapies
- 9.2.1.1. Proton Pump Inhibitor (PPI)
- 9.2.1.2. Others
- 9.2.2. Targeted Therapies
- 9.2.2.1. Antibodies
- 9.2.2.2. JAK Inhibitors
- 9.2.2.3. Others
- 9.2.3. Anti-Inflammatory & Immunomodulators
- 9.2.4. Antibiotics
- 9.2.5. Antiemetics
- 9.2.6. Motility Agents & Secretagogues
- 9.2.7. Others
- 9.2.1. Acid Suppression Therapies
- 9.3. Market Analysis, Insights and Forecast - By Route of Administration
- 9.3.1. Oral
- 9.3.2. Parenteral
- 9.3.3. Others
- 9.4. Market Analysis, Insights and Forecast - By Age Group
- 9.4.1. Pediatrics
- 9.4.2. Adults
- 9.5. Market Analysis, Insights and Forecast - By Application
- 9.5.1. Gastroesophageal Reflux Disease (GERD)
- 9.5.2. Functional Gastrointestinal Disorders (FGIDs)
- 9.5.3. Irritable Bowel Syndrome (IBS)
- 9.5.4. Inflammatory Bowel Disease (IBD)
- 9.5.5. GI Cancers
- 9.5.6. Others
- 9.6. Market Analysis, Insights and Forecast - By Distribution Channel
- 9.6.1. Hospital Pharmacies
- 9.6.2. Retail Pharmacies & Drug Stores
- 9.6.3. Online Pharmacies
- 9.7. Market Analysis, Insights and Forecast - By Country/Sub-region
- 9.7.1. Brazil
- 9.7.2. Mexico
- 9.7.3. Rest of Latin America
10. Middle East & Africa Gastrointestinal Therapeutics Market Analysis, Insights and Forecast, 2021-2034
- 10.1. Market Analysis, Insights and Forecast - By Product Type Type
- 10.1.1. Small Molecules/Conventional Drugs
- 10.1.2. Biologics & Biosimilars
- 10.2. Market Analysis, Insights and Forecast - By Therapy Type
- 10.2.1. Acid Suppression Therapies
- 10.2.1.1. Proton Pump Inhibitor (PPI)
- 10.2.1.2. Others
- 10.2.2. Targeted Therapies
- 10.2.2.1. Antibodies
- 10.2.2.2. JAK Inhibitors
- 10.2.2.3. Others
- 10.2.3. Anti-Inflammatory & Immunomodulators
- 10.2.4. Antibiotics
- 10.2.5. Antiemetics
- 10.2.6. Motility Agents & Secretagogues
- 10.2.7. Others
- 10.2.1. Acid Suppression Therapies
- 10.3. Market Analysis, Insights and Forecast - By Route of Administration
- 10.3.1. Oral
- 10.3.2. Parenteral
- 10.3.3. Others
- 10.4. Market Analysis, Insights and Forecast - By Age Group
- 10.4.1. Pediatrics
- 10.4.2. Adults
- 10.5. Market Analysis, Insights and Forecast - By Application
- 10.5.1. Gastroesophageal Reflux Disease (GERD)
- 10.5.2. Functional Gastrointestinal Disorders (FGIDs)
- 10.5.3. Irritable Bowel Syndrome (IBS)
- 10.5.4. Inflammatory Bowel Disease (IBD)
- 10.5.5. GI Cancers
- 10.5.6. Others
- 10.6. Market Analysis, Insights and Forecast - By Distribution Channel
- 10.6.1. Hospital Pharmacies
- 10.6.2. Retail Pharmacies & Drug Stores
- 10.6.3. Online Pharmacies
- 10.7. Market Analysis, Insights and Forecast - By Country/Sub-region
- 10.7.1. GCC
- 10.7.2. South Africa
- 10.7.3. Rest of Middle East & Africa
11. Competitive Analysis
- 11.1. Global Market Share Analysis (2026)
- 11.2. Company Profiles (Overview, Products, SWOT analysis, Recent developments, strategies, financials (based on availability))
- 11.2.1. Johnson & Johnson
- 11.2.2. AbbVie Inc.
- 11.2.3. Takeda Pharmaceutical Company Limited
- 11.2.4. Bristol-Myers Squibb Company
- 11.2.5. Bayer AG
- 11.2.6. Pfizer Inc.
- 11.2.7. Abbott
- 11.2.8. UCB S.A.
- 11.2.9. Bausch Health Companies Inc.
- 11.2.10. CELLTRION INC.
List of Tables
- Table 1: Global Gastrointestinal Therapeutics Market Revenue (USD Billion) Forecast, By Product Type, 2021-2034
- Table 2: Global Gastrointestinal Therapeutics Market Revenue (USD Billion) Forecast, By Therapy Type, 2021-2034
- Table 3: Global Gastrointestinal Therapeutics Market Revenue (USD Billion) Forecast, By Acid Suppression Therapies, 2021-2034
- Table 4: Global Gastrointestinal Therapeutics Market Revenue (USD Billion) Forecast, By Targeted Therapies, 2021-2034
- Table 5: Global Gastrointestinal Therapeutics Market Revenue (USD Billion) Forecast, By Route of Administration, 2021-2034
- Table 6: Global Gastrointestinal Therapeutics Market Revenue (USD Billion) Forecast, By Age Group, 2021-2034
- Table 7: Global Gastrointestinal Therapeutics Market Revenue (USD Billion) Forecast, By Application, 2021-2034
- Table 8: Global Gastrointestinal Therapeutics Market Revenue (USD Billion) Forecast, By Distribution Channel, 2021-2034
- Table 9: Global Gastrointestinal Therapeutics Market Revenue (USD Billion) Forecast, By Region, 2021-2034
- Table 10: North America Gastrointestinal Therapeutics Market Revenue (USD Billion) Forecast, By Product Type, 2021-2034
- Table 11: North America Gastrointestinal Therapeutics Market Revenue (USD Billion) Forecast, By Acid Suppression Therapies, 2021-2034
- Table 12: North America Gastrointestinal Therapeutics Market Revenue (USD Billion) Forecast, By Targeted Therapies, 2021-2034
- Table 13: North America Gastrointestinal Therapeutics Market Revenue (USD Billion) Forecast, By Therapy Type, 2021-2034
- Table 14: North America Gastrointestinal Therapeutics Market Revenue (USD Billion) Forecast, By Route of Administration, 2021-2034
- Table 15: North America Gastrointestinal Therapeutics Market Revenue (USD Billion) Forecast, By Age Group, 2021-2034
- Table 16: North America Gastrointestinal Therapeutics Market Revenue (USD Billion) Forecast, By Application, 2021-2034
- Table 17: North America Gastrointestinal Therapeutics Market Revenue (USD Billion) Forecast, By Distribution Channel, 2021-2034
- Table 18: North America Gastrointestinal Therapeutics Market Revenue (USD Billion) Forecast, By Country, 2021-2034
- Table 19: Europe Gastrointestinal Therapeutics Market Revenue (USD Billion) Forecast, By Product Type, 2021-2034
- Table 20: Europe Gastrointestinal Therapeutics Market Revenue (USD Billion) Forecast, By Acid Suppression Therapies, 2021-2034
- Table 21: Europe Gastrointestinal Therapeutics Market Revenue (USD Billion) Forecast, By Targeted Therapies, 2021-2034
- Table 22: Europe Gastrointestinal Therapeutics Market Revenue (USD Billion) Forecast, By Therapy Type, 2021-2034
- Table 23: Europe Gastrointestinal Therapeutics Market Revenue (USD Billion) Forecast, By Route of Administration, 2021-2034
- Table 24: Europe Gastrointestinal Therapeutics Market Revenue (USD Billion) Forecast, By Age Group, 2021-2034
- Table 25: Europe Gastrointestinal Therapeutics Market Revenue (USD Billion) Forecast, By Application, 2021-2034
- Table 26: Europe Gastrointestinal Therapeutics Market Revenue (USD Billion) Forecast, By Distribution Channel, 2021-2034
- Table 27: Europe Gastrointestinal Therapeutics Market Revenue (USD Billion) Forecast, By Country/ Sub-region, 2021-2034
- Table 28: Asia Pacific Gastrointestinal Therapeutics Market Revenue (USD Billion) Forecast, By Product Type, 2021-2034
- Table 29: Asia Pacific Gastrointestinal Therapeutics Market Revenue (USD Billion) Forecast, By Acid Suppression Therapies, 2021-2034
- Table 30: Asia Pacific Gastrointestinal Therapeutics Market Revenue (USD Billion) Forecast, By Targeted Therapies, 2021-2034
- Table 31: Asia Pacific Gastrointestinal Therapeutics Market Revenue (USD Billion) Forecast, By Therapy Type, 2021-2034
- Table 32: Asia Pacific Gastrointestinal Therapeutics Market Revenue (USD Billion) Forecast, By Route of Administration, 2021-2034
- Table 33: Asia Pacific Gastrointestinal Therapeutics Market Revenue (USD Billion) Forecast, By Age Group, 2021-2034
- Table 34: Asia Pacific Gastrointestinal Therapeutics Market Revenue (USD Billion) Forecast, By Application, 2021-2034
- Table 35: Asia Pacific Gastrointestinal Therapeutics Market Revenue (USD Billion) Forecast, By Distribution Channel, 2021-2034
- Table 36: Asia Pacific Gastrointestinal Therapeutics Market Revenue (USD Billion) Forecast, By Country/ Sub-region, 2021-2034
- Table 37: Latin America Gastrointestinal Therapeutics Market Revenue (USD Billion) Forecast, By Product Type, 2021-2034
- Table 38: Latin America Gastrointestinal Therapeutics Market Revenue (USD Billion) Forecast, By Acid Suppression Therapies, 2021-2034
- Table 39: Latin America Gastrointestinal Therapeutics Market Revenue (USD Billion) Forecast, By Targeted Therapies, 2021-2034
- Table 40: Latin America Gastrointestinal Therapeutics Market Revenue (USD Billion) Forecast, By Therapy Type, 2021-2034
- Table 41: Latin America Gastrointestinal Therapeutics Market Revenue (USD Billion) Forecast, By Route of Administration, 2021-2034
- Table 42: Latin America Gastrointestinal Therapeutics Market Revenue (USD Billion) Forecast, By Age Group, 2021-2034
- Table 43: Latin America Gastrointestinal Therapeutics Market Revenue (USD Billion) Forecast, By Application, 2021-2034
- Table 44: Latin America Gastrointestinal Therapeutics Market Revenue (USD Billion) Forecast, By Distribution Channel, 2021-2034
- Table 45: Latin America Gastrointestinal Therapeutics Market Revenue (USD Billion) Forecast, By Country/ Sub-region, 2021-2034
- Table 46: Middle East & Africa Gastrointestinal Therapeutics Market Revenue (USD Billion) Forecast, By Product Type, 2021-2034
- Table 47: Middle East & Africa Gastrointestinal Therapeutics Market Revenue (USD Billion) Forecast, By Acid Suppression Therapies, 2021-2034
- Table 48: Middle East & Africa Gastrointestinal Therapeutics Market Revenue (USD Billion) Forecast, By Targeted Therapies, 2021-2034
- Table 49: Middle East & Africa Gastrointestinal Therapeutics Market Revenue (USD Billion) Forecast, By Therapy Type, 2021-2034
- Table 50: Middle East & Africa Gastrointestinal Therapeutics Market Revenue (USD Billion) Forecast, By Route of Administration, 2021-2034
- Table 51: Middle East & Africa Gastrointestinal Therapeutics Market Revenue (USD Billion) Forecast, By Age Group, 2021-2034
- Table 52: Middle East & Africa Gastrointestinal Therapeutics Market Revenue (USD Billion) Forecast, By Application, 2021-2034
- Table 53: Middle East & Africa Gastrointestinal Therapeutics Market Revenue (USD Billion) Forecast, By Distribution Channel, 2021-2034
- Table 54: Middle East & Africa Gastrointestinal Therapeutics Market Revenue (USD Billion) Forecast, By Country/ Sub-region, 2021-2034
List of Figures
- Figure 1: Global Gastrointestinal Therapeutics Market Revenue Breakdown (USD Billion, %) By Region, 2026 & 2034
- Figure 2: Global Gastrointestinal Therapeutics Market Value Share (%), By Product Type, 2026 & 2034
- Figure 3: Global Gastrointestinal Therapeutics Market Value Share (%), By Therapy Type, 2026 & 2034
- Figure 4: Global Gastrointestinal Therapeutics Market Value Share (%), By Route of Administration, 2026 & 2034
- Figure 5: Global Gastrointestinal Therapeutics Market Value Share (%), By Age Group, 2026 & 2034
- Figure 6: Global Gastrointestinal Therapeutics Market Value Share (%), By Application, 2026 & 2034
- Figure 7: Global Gastrointestinal Therapeutics Market Value Share (%), By Distribution Channel, 2026 & 2034
- Figure 8: Global Gastrointestinal Therapeutics Market Value (USD Billion), By Region, 2026 & 2034
- Figure 9: North America Gastrointestinal Therapeutics Market Value (USD Billion), By Product Type, 2026 & 2034
- Figure 10: North America Gastrointestinal Therapeutics Market Value Share (%), By Product Type, 2026
- Figure 11: North America Gastrointestinal Therapeutics Market Value (USD Billion), By Therapy Type, 2026 & 2034
- Figure 12: North America Gastrointestinal Therapeutics Market Value Share (%), By Therapy Type, 2026
- Figure 13: North America Gastrointestinal Therapeutics Market Value (USD Billion), By Route of Administration, 2026 & 2034
- Figure 14: North America Gastrointestinal Therapeutics Market Value Share (%), By Route of Administration, 2026
- Figure 15: North America Gastrointestinal Therapeutics Market Value (USD Billion), By Age Group, 2026 & 2034
- Figure 16: North America Gastrointestinal Therapeutics Market Value Share (%), By Age Group, 2026
- Figure 17: North America Gastrointestinal Therapeutics Market Value (USD Billion), By Application, 2026 & 2034
- Figure 18: North America Gastrointestinal Therapeutics Market Value Share (%), By Application, 2026
- Figure 19: North America Gastrointestinal Therapeutics Market Value (USD Billion), By Distribution Channel, 2026 & 2034
- Figure 20: North America Gastrointestinal Therapeutics Market Value Share (%), By Distribution Channel, 2026
- Figure 21: North America Gastrointestinal Therapeutics Market Value (USD Billion), By Country, 2026 & 2034
- Figure 22: North America Gastrointestinal Therapeutics Market Value Share (%), By Country, 2026
- Figure 23: Europe Gastrointestinal Therapeutics Market Value (USD Billion), By Product Type, 2026 & 2034
- Figure 24: Europe Gastrointestinal Therapeutics Market Value Share (%), By Product Type, 2026
- Figure 25: Europe Gastrointestinal Therapeutics Market Value (USD Billion), By Therapy Type, 2026 & 2034
- Figure 26: Europe Gastrointestinal Therapeutics Market Value Share (%), By Therapy Type, 2026
- Figure 27: Europe Gastrointestinal Therapeutics Market Value (USD Billion), By Route of Administration, 2026 & 2034
- Figure 28: Europe Gastrointestinal Therapeutics Market Value Share (%), By Route of Administration, 2026
- Figure 29: Europe Gastrointestinal Therapeutics Market Value (USD Billion), By Age Group, 2026 & 2034
- Figure 30: Europe Gastrointestinal Therapeutics Market Value Share (%), By Age Group, 2026
- Figure 31: Europe Gastrointestinal Therapeutics Market Value (USD Billion), By Application, 2026 & 2034
- Figure 32: Europe Gastrointestinal Therapeutics Market Value Share (%), By Application, 2026
- Figure 33: Europe Gastrointestinal Therapeutics Market Value (USD Billion), By Distribution Channel, 2026 & 2034
- Figure 34: Europe Gastrointestinal Therapeutics Market Value Share (%), By Distribution Channel, 2026
- Figure 35: Europe Gastrointestinal Therapeutics Market Value (USD Billion), By Country/ Sub-region, 2026 & 2034
- Figure 36: Europe Gastrointestinal Therapeutics Market Value Share (%), By Country/ Sub-region, 2026
- Figure 37: Asia Pacific Gastrointestinal Therapeutics Market Value (USD Billion), By Product Type, 2026 & 2034
- Figure 38: Asia Pacific Gastrointestinal Therapeutics Market Value Share (%), By Product Type, 2026
- Figure 39: Asia Pacific Gastrointestinal Therapeutics Market Value (USD Billion), By Therapy Type, 2026 & 2034
- Figure 40: Asia Pacific Gastrointestinal Therapeutics Market Value Share (%), By Therapy Type, 2026
- Figure 41: Asia Pacific Gastrointestinal Therapeutics Market Value (USD Billion), By Route of Administration, 2026 & 2034
- Figure 42: Asia Pacific Gastrointestinal Therapeutics Market Value Share (%), By Route of Administration, 2026
- Figure 43: Asia Pacific Gastrointestinal Therapeutics Market Value (USD Billion), By Age Group, 2026 & 2034
- Figure 44: Asia Pacific Gastrointestinal Therapeutics Market Value Share (%), By Age Group, 2026
- Figure 45: Asia Pacific Gastrointestinal Therapeutics Market Value (USD Billion), By Application, 2026 & 2034
- Figure 46: Asia Pacific Gastrointestinal Therapeutics Market Value Share (%), By Application, 2026
- Figure 47: Asia Pacific Gastrointestinal Therapeutics Market Value (USD Billion), By Distribution Channel, 2026 & 2034
- Figure 48: Asia Pacific Gastrointestinal Therapeutics Market Value Share (%), By Distribution Channel, 2026
- Figure 49: Asia Pacific Gastrointestinal Therapeutics Market Value (USD Billion), By Country/ Sub-region, 2026 & 2034
- Figure 50: Asia Pacific Gastrointestinal Therapeutics Market Value Share (%), By Country/ Sub-region, 2026
- Figure 51: Latin America Gastrointestinal Therapeutics Market Value (USD Billion), By Product Type, 2026 & 2034
- Figure 52: Latin America Gastrointestinal Therapeutics Market Value Share (%), By Product Type, 2026
- Figure 53: Latin America Gastrointestinal Therapeutics Market Value (USD Billion), By Therapy Type, 2026 & 2034
- Figure 54: Latin America Gastrointestinal Therapeutics Market Value Share (%), By Therapy Type, 2026
- Figure 55: Latin America Gastrointestinal Therapeutics Market Value (USD Billion), By Route of Administration, 2026 & 2034
- Figure 56: Latin America Gastrointestinal Therapeutics Market Value Share (%), By Route of Administration, 2026
- Figure 57: Latin America Gastrointestinal Therapeutics Market Value (USD Billion), By Age Group, 2026 & 2034
- Figure 58: Latin America Gastrointestinal Therapeutics Market Value Share (%), By Age Group, 2026
- Figure 59: Latin America Gastrointestinal Therapeutics Market Value (USD Billion), By Application, 2026 & 2034
- Figure 60: Latin America Gastrointestinal Therapeutics Market Value Share (%), By Application, 2026
- Figure 61: Latin America Gastrointestinal Therapeutics Market Value (USD Billion), By Distribution Channel, 2026 & 2034
- Figure 62: Latin America Gastrointestinal Therapeutics Market Value Share (%), By Distribution Channel, 2026
- Figure 63: Latin America Gastrointestinal Therapeutics Market Value (USD Billion), By Country/ Sub-region, 2026 & 2034
- Figure 64: Latin America Gastrointestinal Therapeutics Market Value Share (%), By Country/ Sub-region, 2026
- Figure 65: Middle East & Africa Gastrointestinal Therapeutics Market Value (USD Billion), By Product Type, 2026 & 2034
- Figure 66: Middle East & Africa Gastrointestinal Therapeutics Market Value Share (%), By Product Type, 2026
- Figure 67: Middle East & Africa Gastrointestinal Therapeutics Market Value (USD Billion), By Therapy Type, 2026 & 2034
- Figure 68: Middle East & Africa Gastrointestinal Therapeutics Market Value Share (%), By Therapy Type, 2026
- Figure 69: Middle East & Africa Gastrointestinal Therapeutics Market Value (USD Billion), By Route of Administration, 2026 & 2034
- Figure 70: Middle East & Africa Gastrointestinal Therapeutics Market Value Share (%), By Route of Administration, 2026
- Figure 71: Middle East & Africa Gastrointestinal Therapeutics Market Value (USD Billion), By Age Group, 2026 & 2034
- Figure 72: Middle East & Africa Gastrointestinal Therapeutics Market Value Share (%), By Age Group, 2026
- Figure 73: Middle East & Africa Gastrointestinal Therapeutics Market Value (USD Billion), By Application, 2026 & 2034
- Figure 74: Middle East & Africa Gastrointestinal Therapeutics Market Value Share (%), By Application, 2026
- Figure 75: Middle East & Africa Gastrointestinal Therapeutics Market Value (USD Billion), By Distribution Channel, 2026 & 2034
- Figure 76: Middle East & Africa Gastrointestinal Therapeutics Market Value Share (%), By Distribution Channel, 2026
- Figure 77: Middle East & Africa Gastrointestinal Therapeutics Market Value (USD Billion), By Country/ Sub-region, 2026 & 2034
- Figure 78: Middle East & Africa Gastrointestinal Therapeutics Market Value Share (%), By Country/ Sub-region, 2026
- Figure 79: Global Gastrointestinal Therapeutics Market Share (%), By Company, 2026
